F. Poordad, J. Mccone, J. Bacon, and B. , Boceprevir for Untreated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1195-1206, 2011.
DOI : 10.1056/NEJMoa1010494
URL : https://hal.archives-ouvertes.fr/hal-00867494

B. Bacon, S. Gordon, and E. Lawitz, Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1207-1217, 2011.
DOI : 10.1056/NEJMoa1009482

I. Jacobson, J. Mchutchison, and G. Dusheiko, Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection, New England Journal of Medicine, vol.364, issue.25, pp.2405-2416, 2011.
DOI : 10.1056/NEJMoa1012912

S. Zeuzem, P. Andreone, and S. Pol, Telaprevir for Retreatment of HCV Infection, New England Journal of Medicine, vol.364, issue.25, pp.2417-2428, 2011.
DOI : 10.1056/NEJMoa1013086

S. Bruno, M. Zuin, and A. Crosignani, Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study, The American Journal of Gastroenterology, vol.147, issue.5, pp.1147-1158, 2009.
DOI : 10.1002/hep.20933

J. Dienstag, M. Ghany, and T. Morgan, A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C, Hepatology, vol.32, issue.Suppl. 1, pp.396-405, 2011.
DOI : 10.1002/hep.24370

N. Kontchou, G. Paries, J. Htar, and M. , Risk Factors for Hepatocellular Carcinoma in Patients With Alcoholic or Viral C Cirrhosis, Clinical Gastroenterology and Hepatology, vol.4, issue.8, pp.1062-1068, 2006.
DOI : 10.1016/j.cgh.2006.05.013

A. Sangiovanni, G. Prati, and P. Fasani, The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients, Hepatology, vol.25, issue.6, pp.1303-1310, 2006.
DOI : 10.1002/hep.21176

S. Bruno, T. Stroffolini, and M. Colombo, Sustained virological response to interferonalpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

V. Mallet, H. Gilgenkrantz, and J. Serpaggi, Brief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis C, Annals of Internal Medicine, vol.149, issue.6, pp.399-403, 2008.
DOI : 10.7326/0003-4819-149-6-200809160-00006

T. Morgan, M. Ghany, and H. Kim, Outcome of sustained virological responders with histologically advanced chronic hepatitis C, Hepatology, vol.137, issue.3, pp.833-844, 2010.
DOI : 10.1002/hep.23744

A. Van-der-meer, B. Veldt, and J. Feld, Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis, JAMA, vol.308, issue.24, pp.2584-2593, 2012.
DOI : 10.1001/jama.2012.144878

S. Bruno, M. Shiffman, and S. Roberts, Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis, Hepatology, vol.47, issue.Suppl 2, pp.388-397, 2010.
DOI : 10.1002/hep.23340

F. Marrache, Y. Consigny, and M. Ripault, Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis, Journal of Viral Hepatitis, vol.113, issue.4, pp.421-428, 2005.
DOI : 10.1016/S0140-6736(98)07236-5

J. Carrion, E. Martinez-bauer, and G. Crespo, Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study, Journal of Hepatology, vol.50, issue.4, pp.719-728, 2009.
DOI : 10.1016/j.jhep.2008.11.015

S. Pol, S. Roberts, and P. Andreone, Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE phase III study, Hepatology, vol.54, pp.374-379, 2011.

H. Fontaine, K. Petitprez, and F. Roudot-thoraval, Guidelines for the diagnosis of uncomplicated cirrhosis, Gastroent??rologie Clinique et Biologique, vol.31, issue.5, pp.504-509, 2007.
DOI : 10.1016/S0399-8320(07)89420-6

S. Chevaliez, M. Bouvier-alias, and R. Brillet, Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method, Hepatology, vol.44, issue.1, pp.22-31, 2007.
DOI : 10.1002/hep.21656

S. Chevaliez, M. Bouvier-alias, and J. Pawlotsky, Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification, Journal of Clinical Microbiology, vol.47, issue.6, pp.1726-1732, 2009.
DOI : 10.1128/JCM.01300-08
URL : https://hal.archives-ouvertes.fr/inserm-00395281

P. Cacoub, M. Bourlière, and J. Lubbe, Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals, Journal of Hepatology, vol.56, issue.2, pp.455-463, 2012.
DOI : 10.1016/j.jhep.2011.08.006

C. Hézode, H. Fontaine, and C. Dorival, Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) ??? NCT01514890, Journal of Hepatology, vol.59, issue.3, pp.434-441, 2013.
DOI : 10.1016/j.jhep.2013.04.035

S. Bruno, J. Vierling, and R. Esteban, Efficacy and safety of boceprevir plus peginterferon???ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis, Journal of Hepatology, vol.58, issue.3, pp.479-487, 2013.
DOI : 10.1016/j.jhep.2012.11.020

J. Vierling, M. Davis, and S. Flamm, Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response, Journal of Hepatology, vol.60, issue.4, pp.168-827800881, 2013.
DOI : 10.1016/j.jhep.2013.12.013

F. Poordad, E. Lawitz, and K. Reddy, Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection???A Randomized Trial, Gastroenterology, vol.145, issue.5, pp.1035-1044, 2013.
DOI : 10.1053/j.gastro.2013.07.051

R. Roomer, B. Hansen, and H. Janssen, Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C, Hepatology, vol.74, issue.Suppl. 4, pp.1225-1231, 2010.
DOI : 10.1002/hep.23842

E. Gomez, Y. Rodriguez, and L. Bertot, The natural history of compensated HCV-related cirrhosis: A prospective long-term study, Journal of Hepatology, vol.58, issue.3, pp.434-444, 2013.
DOI : 10.1016/j.jhep.2012.10.023

W. Alazawi, M. Cunningham, J. Dearden, and G. Foster, Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection, Alimentary Pharmacology & Therapeutics, vol.137, issue.Suppl. 1, pp.344-355, 2010.
DOI : 10.1111/j.1365-2036.2010.04370.x
URL : https://hal.archives-ouvertes.fr/hal-00552579

D. Bisceglie, A. Shiffman, M. Everson, and G. , Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon, New England Journal of Medicine, vol.359, issue.23, pp.2429-2441, 2008.
DOI : 10.1056/NEJMoa0707615

J. Vierling, S. Zeuzem, and F. Poordad, 1430 SAFETY AND EFFICACY OF BOCEPREVIR/PEGINTERFERON/ RIBAVIRIN (BOC/P/R) COMBINATION THERAPY FOR CHRONIC HCV G1 PATIENTS WITH COMPENSATED CIRRHOSIS: A META-ANALYSIS OF FIVE PHASE 3 CLINICAL TRIALS, Journal of Hepatology, vol.58, p.576, 2013.
DOI : 10.1016/S0168-8278(13)61429-4

M. Sulkowski, D. Gardiner, and M. Rodriguez-torres, Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection, New England Journal of Medicine, vol.370, issue.3, pp.211-221, 2014.
DOI : 10.1056/NEJMoa1306218

I. Jacobson, R. Ghalib, and M. Rodriguez-torres, SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: The COSMOS study, Hepatology, vol.58, pp.1379-1380, 2013.

. Anaemia, Grade 2: 8.0 to ? 9.0 g/dL Grade 3/4: < 8.0 g/dL Erythropoietin use Blood transfusion 57 (19.1), pp.35-46

. Neutropenia, n (%) Grade 3: 500 to < 750

. Anaemia, Grade 2: 8·0 to ? 9

. Neutropenia, n (%) Grade 3: 500 to < 750

?. Serum-albumin and /. Patients, Patients with severe complications or death, n (%) Patients with SVR12, n (%) 306 (68, 3%) 19 (6.2%) 168 (54.9%), pp.74-90

<. Serum-albumin and /. Patients, Patients with severe complications or death, n (%) Patients with SVR12, p.31